The FDA wants to make it harder to offer genetic testing directly to consumers, by demanding that 23andMe stop marketing its DNA testing until further word from the FDA. The FDA says that risk of inaccurate results poses too great of a treat to the public. Some of the tests offered examine genetic mutations that may cause breast or ovarian cancer. The FDA says inaccurate results may lead to unnecessary mastectomy or other procedures.

Read the full article here:
FDA Demands a Halt to a DNA Test Kit’s Marketing – New York Times